Literature DB >> 23740600

Establishment and serial passage of cell cultures derived from LuCaP xenografts.

Sarah R Young1, Matthias Saar, Jennifer Santos, Holly M Nguyen, Robert L Vessella, Donna M Peehl.   

Abstract

BACKGROUND: LuCaP serially transplantable xenografts derived from primary and metastatic human prostate cancer encompass the molecular and cellular heterogeneity of the disease and are an invaluable resource for in vivo preclinical studies. A limitation of this model, however, has been the inability to establish and passage cell cultures derived from the xenografts. Here, we describe a novel spheroid culture system that supports long-term growth of LuCaP cells in vitro.
METHODS: Xenografts were minced and digested with collagenase. Tissue dissociation was terminated while the majority of cells remained as clusters rather than single cells. The cell clusters were suspended in StemPro medium supplemented with R1881 and Y-27632, a Rho kinase inhibitor, and placed in ultralow attachment dishes for spheroid culture. Serial passage was achieved by partial digestion to small clusters with trypsin/EDTA in the presence of Y-27632. Cell viability, growth and phenotype were monitored with LIVE/DEAD®, MTS, qRT-PCR, and immunocytochemical assays.
RESULTS: Cells from six LuCaP xenografts formed proliferating spheroids that were serially passaged a minimum of three times and cryopreserved. Two of the cell lines, LuCaP 136 and LuCaP 147, were further passaged and characterized. Both expressed biomarkers characteristic of the xenografts of origin, were determined to be of independent origin by STR fingerprinting, and were free of mycoplasma. LuCaP 147 formed tumors similar to the original xenograft when injected into mice.
CONCLUSIONS: The ability to culture LuCaP cells affords new opportunities for fast, cheap, and efficient preclinical studies and extends the value of the LuCaP xenograft models.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  preclinical model; prostate cancer; spheroids

Mesh:

Year:  2013        PMID: 23740600      PMCID: PMC3720815          DOI: 10.1002/pros.22610

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  28 in total

1.  LuCaP 35: a new model of prostate cancer progression to androgen independence.

Authors:  Eva Corey; Janna E Quinn; Kent R Buhler; Peter S Nelson; Jill A Macoska; Lawrence D True; Robert L Vessella
Journal:  Prostate       Date:  2003-06-01       Impact factor: 4.104

2.  Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture.

Authors:  Shuangling Chen; Lorenzo Principessa; John T Isaacs
Journal:  Prostate       Date:  2012-03-06       Impact factor: 4.104

3.  VCaP, a cell-based model system of human prostate cancer.

Authors:  S Korenchuk; J E Lehr; L MClean; Y G Lee; S Whitney; R Vessella; D L Lin; K J Pienta
Journal:  In Vivo       Date:  2001 Mar-Apr       Impact factor: 2.155

Review 4.  Primary cell cultures as models of prostate cancer development.

Authors:  D M Peehl
Journal:  Endocr Relat Cancer       Date:  2005-03       Impact factor: 5.678

5.  Determination of subcutaneous tumor size in athymic (nude) mice.

Authors:  M M Tomayko; C P Reynolds
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 6.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 1.

Authors:  R E Sobel; M D Sadar
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

7.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

Authors:  Lawrence D True; Kent Buhler; Janna Quinn; Emily Williams; Peter S Nelson; Nigel Clegg; Jill A Macoska; Thomas Norwood; Alvin Liu; William Ellis; Paul Lange; Robert Vessella
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 8.  The use of 3-D cultures for high-throughput screening: the multicellular spheroid model.

Authors:  Leoni A Kunz-Schughart; James P Freyer; Ferdinand Hofstaedter; Reinhard Ebner
Journal:  J Biomol Screen       Date:  2004-06

9.  Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture.

Authors:  A H Cory; T C Owen; J A Barltrop; J G Cory
Journal:  Cancer Commun       Date:  1991-07

10.  Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.

Authors:  W J Ellis; R L Vessella; K R Buhler; F Bladou; L D True; S A Bigler; D Curtis; P H Lange
Journal:  Clin Cancer Res       Date:  1996-06       Impact factor: 12.531

View more
  17 in total

1.  3D Tumor Spheroid Models for In Vitro Therapeutic Screening of Nanoparticles.

Authors:  Simonas Daunys; Agnė Janonienė; Indrė Januškevičienė; Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  The recurrent architecture of tumour initiation, progression and drug sensitivity.

Authors:  Andrea Califano; Mariano J Alvarez
Journal:  Nat Rev Cancer       Date:  2016-12-15       Impact factor: 60.716

Review 3.  Reprogramming of prostate cancer cells--technical challenges.

Authors:  Gisely T Borges; Eneida F Vêncio; Ricardo Z N Vêncio; Robert L Vessella; Carol B Ware; Alvin Y Liu
Journal:  Curr Urol Rep       Date:  2015-01       Impact factor: 3.092

4.  Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.

Authors:  Maija P Valta; Hongjuan Zhao; Matthias Saar; Johanna Tuomela; Rosalie Nolley; Johannes Linxweiler; Jouko Sandholm; Jaakko Lehtimäki; Pirkko Härkönen; Ilsa Coleman; Peter S Nelson; Eva Corey; Donna M Peehl
Journal:  Clin Exp Metastasis       Date:  2016-02-12       Impact factor: 5.150

5.  Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.

Authors:  Manish Kohli; Yeung Ho; David W Hillman; Jamie L Van Etten; Christine Henzler; Rendong Yang; Jamie M Sperger; Yingming Li; Elizabeth Tseng; Ting Hon; Tyson Clark; Winston Tan; Rachel E Carlson; Liguo Wang; Hugues Sicotte; Ho Thai; Rafael Jimenez; Haojie Huang; Peter T Vedell; Bruce W Eckloff; Jorge F Quevedo; Henry C Pitot; Brian A Costello; Jin Jen; Eric D Wieben; Kevin A T Silverstein; Joshua M Lang; Liewei Wang; Scott M Dehm
Journal:  Clin Cancer Res       Date:  2017-05-04       Impact factor: 12.531

Review 6.  Drug discovery in prostate cancer mouse models.

Authors:  Kenneth C Valkenburg; Kenneth J Pienta
Journal:  Expert Opin Drug Discov       Date:  2015-06-01       Impact factor: 6.098

7.  Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.

Authors:  Matthias Saar; Hongjuan Zhao; Rosalie Nolley; Sarah R Young; Ilsa Coleman; Peter S Nelson; Robert L Vessella; Donna M Peehl
Journal:  Cancer Lett       Date:  2014-07-03       Impact factor: 8.679

Review 8.  Liquid-based three-dimensional tumor models for cancer research and drug discovery.

Authors:  Stephanie L Ham; Ramila Joshi; Pradip S Thakuri; Hossein Tavana
Journal:  Exp Biol Med (Maywood)       Date:  2016-04-11

9.  Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.

Authors:  Nazanin Ruppender; Sandy Larson; Bryce Lakely; Lori Kollath; Lisha Brown; Ilsa Coleman; Roger Coleman; Holly Nguyen; Peter S Nelson; Eva Corey; Linda A Snyder; Robert L Vessella; Colm Morrissey; Hung-Ming Lam
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

Review 10.  Overcoming biological barriers to improve solid tumor immunotherapy.

Authors:  Anvay Ukidve; Katharina Cu; Ninad Kumbhojkar; Joerg Lahann; Samir Mitragotri
Journal:  Drug Deliv Transl Res       Date:  2021-02-20       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.